Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered peptides and therapeutic proteins, announced today the execution of the following key milestones:

Intuitive Venture PartnersJuly 18, 20222022, entera bio

Entera Bio Announces Positive Topline EB613 Phase 2 Biomarker Data

Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) announces positive topline EB613 phase 2 biomarker data

Intuitive Venture PartnersApril 6, 2021entera bio, 2021

Entera Bio Announces FDA Approval of IND Application for EB613 – an Oral Human Parathyroid Hormone (1-34) for the Treatment of Osteoporosis

Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) announces FDA approval of IND application for EB613 – an oral human parathyroid hormone (1-34) for the treatment of osteoporosis

Intuitive Venture PartnersDecember 10, 2020entera bio, 2020

Entera Bio Ltd Announces Completion of Enrollment In Phase 2 Clinical Trial of Eb613 In Osteoporosis

Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) announces completion of enrollment in phase 2 clinical trial of Eb613 In osteoporosis

Intuitive Venture PartnersNovember 9, 2020entera bio, 2020

Entera Bio Reports Positive Results From a Phase 2 PK/PD Study

Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) reports positive results from a phase 2 PK/PD study of Oral PTH (1-34) in patients with hypoparathyroidism.

Intuitive Venture PartnersSeptember 23, 2019entera bio, 2019

Entera Bio Announces Positive Feedback and Guidance from the US FDA

Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) announced today the positive outcome of a pre-IND meeting held with the US Food and Drug Administration (FDA) to disscuss the Company’s development plan for Oral PTH for the treatment of osteoporosis.

Intuitive Venture PartnersJanuary 31, 2019entera bio, 2019

Entera Bio and Amgen Enter Strategic Research Collaboration in Inflammatory Disease and Other Serious Illnesses

Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) announced today that it has entered into a research collaboration and license agreement with Amgen in inflammatory disease and other serious illnesses.

Intuitive Venture PartnersDecember 11, 2018entera bio, 2018

Entera Bio Reports Positive Results from Study of Oral PTH in Patients with Hypoparathyroidism

Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) announced today that it has received positive results from the first part of its pharmacokinetic (PK) and pharmacodynamic (PD) study in patients with hypoparathyroidism treated with its oral parathyroid hormone (PTH) drug.

Intuitive Venture PartnersNovember 8, 2018entera bio, 2018

Entera Bio Appoints Two New External Independent Members to the Board of Directors

Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) announced today the appointment of Faith L. Charles and Miranda J. Toledano to the company’s board of directors, effective immediately.

Intuitive Venture PartnersOctober 2, 2018entera bio, 2018

Entera Bio Appoints Dr. Arthur Santora as Chief Medical Officer

Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) today announced the appointment of Arthur C. Santora II, MD, PhD as its new Chief Medical Officer, effective immediately.

Intuitive Venture PartnersSeptember 21, 2018entera bio, 2018

Entera Bio Reports Second Quarter 2018 Financial Results and Operating Update

Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) today announced its second quarter 2018 financial results and provided an operating update.

pharmaceuticalIntuitive Venture PartnersAugust 20, 2018entera bio, 2018

Entera Bio Ltd. Announces Appointment of Mr. Gerald Lieberman as Chairman of the Board of Directors

Entera Bio Ltd. (NASDAQ: ENTX and ENTXW), announced today the appointment of Mr. Gerald Lieberman as the chairman of the board of directors, effective as of August 6, 2018.

READ MORE

Intuitive Venture PartnersAugust 9, 2018entera bio, 2018